Skip to content

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

Viral Lung Infection and Acute Respiratory Failure

The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

null

Conditions de participation

  • Sexe:

    ALL
  • Âges admissibles:

    18 and up

Critères de participation

Inclusion Criteria:

* Adult participants ≥ 18 years old at the time of signing the informed consent form.
* Patients hospitalised with viral lung infection.
* Hypoxaemia requiring treatment with supplemental O2.

Hypoxaemia is defined as:

SpO2 ≤ 90% OR

SpO2 ≤ 92% AND one or both of the following:

Radiographic infiltrates by CXR/CT compatible with viral lung infection per investigator judgement.

Use of accessory muscles of respiration or RR (respiratory rate) \> 22.

- Patient remains hypoxaemic at randomisation requiring treatment with supplemental oxygen.

Exclusion Criteria:

* Known fungal or parasitic lung infection, aspiration lung infection, lung abscess, or evidence of septic shock. Bacterial co-infection is allowed, unless, in the opinion of the investigator, bacterial infection defines the severity of the participant's condition.
* Hypoxaemia caused primarily by extrapulmonary insult or by lung injury of non-infective aetiology.
* Ongoing IMV/ECMO at randomisation.

Lieu de l'étude

Research Site
Research Site
New Westminster, British Columbia
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Levis, Quebec
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Saskatoon, Saskatchewan
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Winnipeg, Manitoba
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Brampton, Ontario
Canada

Contactez l'équipe d'étude

Research Site
Research Site
Montreal, Quebec
Canada

Contactez l'équipe d'étude

Étude parrainée par
AstraZeneca
Participants recherchés
Plus d'informations
ID de l'étude: NCT05624450